Learn more about SKYRIZI® (risankizumab‐rzaa)
Learn how AbbVie could help you save on SKYRIZI. symptom relief in 4 conditions. See if it may be right for you. SKYRIZI is a biologic that has been prescribed to more than 200,000 patients in the USA. * Includes adults with: Plaque Psoriasis, Psoriatic Arthritis, and Crohn’s disease.
SKYRIZI® (risankizumab-rzaa) HCP - Official Site by AbbVie Inc.
A biologic treatment for adult patients living with moderate to severe Plaque Psoriasis, adults with active Psoriatic Arthritis, adults with moderate to severe active Crohn's Disease, and adults with moderate to severe Ulcerative Colitis. See SKYRIZI® (risankizumab-rzaa) Important Safety Information for risks & safety details.
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative …
NORTH CHICAGO, Ill., June 18, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and ...
AbbVie breaks new ground for IL-23 drug Skyrizi in IBD
Jun 20, 2024 · AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) –...
Patient Access & Support | SKYRIZI® (risankizumab-rzaa)
AbbVie is committed to providing reliable access and support for your SKYRIZI patients. Download the Skyrizi Complete enrollment & prescription form. See Important Safety Information and Prescribing Information.
Skyrizi Complete | Patient Support & Resources
At no additional cost, Skyrizi Complete offers support, potential ways to save, answers to your treatment and insurance questions, and a dedicated Nurse Ambassador* to help you get started and stay on track with your prescribed treatment plan.
SKYRIZI® Programs, Support & Resources | AbbVie Access®
Help patients identify potential savings options. Find and access programs, support and resources for SKYRIZI® (risankizumab-rzaa). See full prescribing information.
AbbVie's SKYRIZI® (risankizumab) Met All Primary and …
Sep 12, 2023 · SKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. 4 IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases. 5 SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for the...
AbbVie Announces European Commission Approval of SKYRIZI
Jul 26, 2024 · SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
What Is SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis?
SKYRIZI is a type of biologic called an interleukin-23 inhibitor (IL-23i). Already approved for adults with moderate to severe Crohn’s disease, SKYRIZI can help deliver results, including significant symptom relief, for adults with moderate to severe ulcerative colitis (UC).